| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |